EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges

Hamza Alasbily, Muna Saad Elburki

Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 736-747

DOI: 10.1007/s43441-026-00945-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 02.03.2026. Verfasst von Hamza Alasbily und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Science, Faculty of Dentistry, University of Benghazi, Benghazi, Libya. Hauptthemen laut MEDLINE: Metformin, Periodontal Diseases, Hypoglycemic Agents. Die Arbeit nennt 71 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Periodontal disease is a chronic inflammatory disorder that gradually destroys tooth-supporting tissues including the alveolar bone, periodontal ligament, and cementum. In recent years, interest has grown in repurposing metformin, a well-known oral antidiabetic drug, as an adjunct to periodontal therapy. Experimental studies have indicated that metformin can aid periodontal healing by promoting stem cell-driven regeneration, enhancing osteoblast activity, and reducing osteoclast-mediated resorption. Clinical trials have further reported that both systemic and local applications of metformin, when used alongside conventional non-surgical treatment, can improve probing depth, clinical attachment, and radiographic markers of bone recovery. However, the results remain inconsistent across study designs, dosage strategies, and delivery methods, and concerns about safety and long-term outcomes persist. This review examines the potential role of metformin in periodontal therapy, with a focus on its mechanisms of action, clinical and experimental evidence, and the current challenges of its use in periodontology. Overall, metformin shows promise as a host-modulatory and regenerative adjunct in periodontal therapy, warranting further large-scale clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminPeriodontal DiseasesHypoglycemic AgentsHumansAnimals

Stichwörter der Autor:innen

InflammationMetforminPeriodontal diseasePeriodontitis

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Basic Medical Science, Faculty of Dentistry, University of Benghazi, Benghazi, Libya.
  • Department of Periodontics, Faculty of Dentistry, University of Benghazi, Benghazi, Libya. muna.elburki@uob.edu.ly.

Zitieren

APA

Alasbily, H., & Elburki, M. S. (2026). Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges. Therapeutic Innovation & Regulatory Science, 60(3), 736-747. https://doi.org/10.1007/s43441-026-00945-9

Vancouver

Alasbily H, Elburki MS. Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges. Therapeutic Innovation & Regulatory Science. 2026;60(3):736-747. doi:10.1007/s43441-026-00945-9

BibTeX
@article{Alasbily2026,
  author = {Alasbily, Hamza and Elburki, Muna Saad},
  title = {Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {3},
  pages = {736--747},
  doi = {10.1007/s43441-026-00945-9}
}
Kostenlos starten →